BIOSENSE WEBSTER INC NOGA XP CARDIAC NAVIGATION SYSTEM; COMPUTER, DIAGNOSTIC, PROGRAMMABLE
|
Back to Search Results |
|
Catalog Number UNK_NOGA XP |
Device Problem
Patient Device Interaction Problem (4001)
|
Patient Problems
Stroke/CVA (1770); Tachycardia (2095)
|
Event Date 12/21/2019 |
Event Type
Injury
|
Event Description
|
This complaint is from a literature source.The following literature cite has been reviewed: mathiasen ab, qayyum aa, jørgensen e, helqvist s, kofoed kf, haack-sørensen m, ekblond a, kastrup j.Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the msc-hf trial.Eur j heart fail.2020 may;22(5):884-892.Doi: 10.1002/ejhf.1700.Epub 2019 dec 21.Pmid: 31863561.Objective/methods/study data: the mesenchymal stromal cells- heart failure trial was a phase ii, single-center, randomized, double-blind, placebo-controlled study.The study assessed 4-year outcomes of intramyocardial injections of autologous bone marrow-derived mesenchymal stromal cells in 60 patients with ischemic heart failure, new york heart association class ii¿iii, left ventricular ejection fraction <45% and no further treatment options were treated between april 2009 and september 2008.Patients were randomized 2:1 to intramyocardial injections of mesenchymal stromal cells or placebo.Lot, model and catalog number are not available, but the suspected biosense device possibly associated with reported adverse events: noga-xp.Concomitant other biosense webster devices that were also used in this study: myostar injection catheters.Concomitant non-biosense webster devices that were also used in this study: n/a.Adverse event(s) and provided interventions: there were two serious adverse events in relation to the noga procedure: one patient with a history of ventricular tachycardia developed ventricular tachycardia during the noga mapping procedure.The patient reverted to sinus rhythm by his implantable cardioverter-defibrillator unit and the procedure was canceled.One patient experienced double-vision and dizziness during the injection procedure.Cerebral ct afterward was normal, but the incident was diagnosed as a minor stroke by the neurologist.The patient was without sequelae and completed the follow-up.
|
|
Manufacturer Narrative
|
This complaint is from a literature source.The following literature cite has been reviewed: mathiasen ab, qayyum aa, jørgensen e, helqvist s, kofoed kf, haack-sørensen m, ekblond a, kastrup j.Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the msc-hf trial.Eur j heart fail.2020 may;22(5):884-892.Doi: 10.1002/ejhf.1700.Epub 2019 dec 21.Pmid: 31863561.No device was received for analysis at the time of submission of the initial 3500a.Since the product was not returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because the lot number was provided by the customer.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer¿s reference number: (b)(4).
|
|
Search Alerts/Recalls
|
|
|